Skip to main content
. 2013 Dec;15(12):1314–1329. doi: 10.1593/neo.131718

Figure 6.

Figure 6

NA co-administration with GNE-617 in NAPRT1-deficient tumors increases tumor NAD and NAM levels in vivo. MiaPaCa-2 (A), PC3 (B), and HT-1080 (C) tumor xenografts (n = 5 per model) were treated with vehicle (control), NA (100 and 30 mg/kg, twice daily), GNE-617 (once daily), or the combination of both agents at the doses shown for 5 days, and tumors were harvested 1 hour following the final dose for measurement of NAD levels by LC-MS/MS as described in Materials and Methods section. MiaPaCa-2 (D), PC3 (E), and HT-1080 (F) tumor xenografts (n = 5 per group) were treated with vehicle (control), NA (100 and 30 mg/kg, twice daily), GNE-617, or the combination of both agents for 5 days, and tumors were harvested 1 hour following the final dose for measurement of NAM levels by LC-MS/MS as described in Materials and Methods section. Comparisons between treated groups and control (vehicle) were determined by Dunnett method: ***P < .0001. Comparisons between treatment groups were performed using unpaired t test assuming unequal variances: #P < .01.